Market News

Stay updated with the latest market trends, earnings, and economic indicators.

Showing news for:NOVARTIND
Clear all filters
Novartis India launches Pluvicto for prostate cancer treatment
negative
ET Markets - Industry 26d ago

Novartis India launches Pluvicto for prostate cancer treatment

Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer cells, offering a new treatment approach for metastatic prostate cancer. The therapy will be available through select hospitals and nuclear medicine centers across India.

NOVARTINDPRECISIONAutomobile and Auto ComponentsHealthcare
India needs to remain attractive for innovation-led investment: Judith Love, Novartis
positive
ET Markets - Industry 30d ago

India needs to remain attractive for innovation-led investment: Judith Love, Novartis

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The company underscores the importance of collaboration to tackle obstacles like high costs and inadequate infrastructure.

BFINVESTNOVARTINDFinancial ServicesHealthcare
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study
negative
ET Markets - Industry 41d ago

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.

FOCUSNOVARTINDConsumer DurablesHealthcare
NEWS
positive
Business Standard - Markets 60d ago

Novartis India standalone net profit declines 13.82% in the March 2026 quarter

Sales rise 7.95% to Rs 90.55 crore

NOVARTINDHealthcare
Q4 Results LIVE Updates: Dr. Reddy's, Dixon report results today; Indian Hotels, Anant Raj react
positive
CNBC TV18 - Markets 60d ago

Q4 Results LIVE Updates: Dr. Reddy's, Dixon report results today; Indian Hotels, Anant Raj react

Q4 Results LIVE Updates: Its an earnings-heavy day on the Dalal Street today. Nifty 50 stock Dr Reddy's Laboratories is scheduled to report its numbers today. Dixon Tech, Berger Paints, Nazara Tech, INOX India, Cohance Lifesciences, Gopal Snacks, Kalpataru, KPR Mill, Max Financial Services, MobiKwik, MTAR Tech, Novartis, Pfizer, Religare, Keystone Developers, Sagility, Tata Power, Torrent Power, Texmaco Rail, V-Guard Industries, are among the other important results to track today. Watch this space for all the LIVE earnings updates.

ALLETECANANTRAJBERGEPAINTBFSICOHANCEDIXONDRREDDYGOPALGVPILINDHOTELINOXINDIAJMFINANCILKALPATARUKPRMILLMAXINDMFSLMOBIKWIKMTARTECHNAZARANETFNOVARTINDNPBETPFIZERRELIGARESAGILITYTATAPOWERTATATECHTECHTEXINFRATEXRAILTNIDETFTORNTPOWERVGUARDVIVIANAZTECHCapital GoodsConstruction
Novartis expands India role in global drug development
positive
ET Markets - Industry 61d ago

Novartis expands India role in global drug development

Novartis is focusing on innovative medicines in India. The company is expanding its role in global drug development. Early-stage research is now happening in India. Novartis plans to launch more new medicines soon. This strategy reinforces its commitment to the Indian market and its significant employee base.

GLOBALIREDANOVARTINDConsumer ServicesFinancial Services